Aurora kinase A enables collective invasion and metastasis by endowing a leader cell phenotype and stabilizing Eplin-mediated cohesion with follower cells

This study demonstrates that Aurora kinase A (AURKA) drives collective breast cancer invasion and metastasis by establishing a leader cell phenotype through centrosome polarization and by stabilizing cell-cell cohesion via its interaction with the actin regulator EPLIN.

The Gist

The Big Picture: How Cancer Spreads in a Group

Imagine a tumor isn't just a pile of loose sand, but a marching band. To spread (metastasize) to new parts of the body, these cancer cells don't just wander off individually; they move together in a coordinated group.

In this "marching band," there are two types of cells:

1. Leader Cells: The ones at the front, breaking the path and telling everyone where to go.
2. Follower Cells: The ones right behind, holding hands and following the leader.

This study discovered a specific "engine" inside the leader cells that makes this group movement possible. That engine is a protein called AURKA.

---

The Story of the "Engine" (AURKA)

1. The Engine is Overactive in Dangerous Spots

The researchers looked at data from patients whose cancer had spread to the liver or lymph nodes. They found that in these dangerous, spreading areas, the "engine" (AURKA) was revving very high.

• The Analogy: Think of a car. If you see a car with a massive, roaring engine, you know it's built for speed and power. The researchers found that cancer cells with this "super-engine" are much more likely to crash into new territories (metastasize) and are linked to shorter survival times for patients.

2. Building a Leader Cell

The team took normal, healthy breast cells (which usually stay put) and gave them a boost of this AURKA engine.

• The Result: Suddenly, these normal cells started acting like the "bad guys." They formed a leader at the front, grabbed onto their neighbors, and started marching out of the group to invade new areas.
• The Analogy: It's like taking a quiet librarian and giving them a megaphone and a map. Suddenly, they aren't just sitting at a desk; they are leading a parade out of the library.

3. The "Glue" Problem

Here is the most critical part. For the group to move together, the followers need to stay glued to the leader. If the glue breaks, the group falls apart, and the invasion fails.

• The Glue: The cells use a protein called E-cadherin (like molecular Velcro) to stick together.
• The Problem: When the researchers turned off the AURKA engine, the glue dissolved. The leader cell lost its direction, and the follower cells scattered like a flock of birds startled by a predator. They couldn't move as a team anymore.

4. The Secret Mechanic: EPLIN

How does AURKA keep the glue strong? The study found it works with a helper protein called EPLIN.

• The Mechanic: EPLIN is like a construction worker who reinforces the Velcro strips between the cells.
• What happens when the engine stops? When AURKA is turned off, the construction worker (EPLIN) gets confused. Instead of staying at the "Velcro" (the cell junctions) to hold the team together, EPLIN runs to the front of the line (the leading edge) and starts messing with the wrong things.
• The Consequence: Without EPLIN at the junctions, the Velcro falls apart. The leader loses its grip on the followers, and the collective invasion collapses.

---

The Experiments (The "Proof")

1. The Chicken Test: The researchers put these cells into chicken embryos (a common test for how cancer spreads).

   • Without AURKA: The cells stayed put or died.
   • With AURKA: The cells grew, formed new structures, and spread to the liver and lungs of the chick. It proved that AURKA alone is enough to turn a harmless cell into a metastatic invader.

2. The Scratch Test: They scratched a line through a layer of cells (like scratching a table) and watched them try to heal the gap.

   • Normal cells: Moved slowly.
   • Cells with AURKA: Rushed to fill the gap, forming a strong, coordinated line.
   • Cells with AURKA turned off: The leader got lost, the followers let go, and the group scattered, failing to close the gap.

Why This Matters (The Takeaway)

This study tells us that AURKA is the boss of the invasion. It does two main jobs:

1. It turns a cell into a Leader (giving it direction).
2. It keeps the Followers glued to the Leader (preventing them from scattering).

The Good News: Because AURKA is so important for this process, stopping it might stop cancer from spreading.

• The Solution: There are already drugs (like MLN8237/Alisertib) that can "turn off" this engine. The study shows that when you use these drugs, the cancer cells lose their ability to march together. They scatter, lose their direction, and can't invade new tissues.

Summary in One Sentence

Cancer cells need a specific protein (AURKA) to act as a team leader and keep their "glue" strong; if we can disable this protein, the cancer team falls apart and can't spread to new parts of the body.

Technical Summary

1. Problem Statement

Breast cancer metastasis is the primary cause of mortality in breast cancer patients. The metastatic cascade often initiates with collective cell invasion, where groups of tumor cells migrate together into surrounding tissues. This process is frequently guided by specialized "leader cells" that possess distinct molecular and morphological features (e.g., front-rear polarity, lamellipodia extension) compared to "follower cells."

While the role of cell cycle progression and epithelial-to-mesenchymal transition (EMT) in metastasis is known, the specific molecular mechanisms that:

1. Define the leader cell phenotype during collective migration.
2. Maintain the physical cohesion between leader and follower cells.
3. Drive the transition from localized invasion to distant metastasis.

remain incompletely understood. Specifically, the role of Aurora Kinase A (AURKA)—a kinase typically associated with mitosis—in non-mitotic collective invasion and metastasis requires further elucidation.

2. Methodology

The study employed a multi-faceted approach combining bioinformatics, in vivo animal models, and in vitro cellular assays:

• Bioinformatics & Meta-Analysis:

  • Analyzed single-cell RNA sequencing (scRNA-seq) data from metastatic breast cancer patients (liver, axilla, and primary breast sites) to identify pathway enrichments (Hallmark gene sets).
  • Correlated AURKA expression with metastasis/invasion signatures across pan-cancer datasets (MSigDB).
  • Analyzed survival data (Overall Survival, Disease-Free Survival) from METABRIC and TCGA datasets to assess the prognostic value of AURKA.

• In Vivo Models (Chicken Embryo CAM):

  • Used the Chorioallantoic Membrane (CAM) assay in immune-incompetent chicken embryos to test metastatic potential.
  • Cell Lines: Non-malignant human breast epithelial cells (MCF10A) engineered to express:
    • GFP-control (GFP-CTRL).
    • GFP-AURKA (overexpression).
    • Luciferase reporters for bioluminescence imaging.
  • Assays: Cells were implanted via "onplant" (Matrigel) or intra-amniotic injection. Metastatic outgrowths were quantified via bioluminescence imaging and histological analysis (H&E, immunofluorescence for GFP, E-cadherin, K14, Vimentin).

• In Vitro Assays:

  • Scratch Wound Assays: Used to model collective migration. Cells were imaged via live-cell microscopy (Incucyte, ImageXpress) to track wound closure, leader cell emergence, and cell scattering.
  • Pharmacological Inhibition: Used MLN8237 (Alisertib), a specific AURKA inhibitor, and MG132, a proteasome inhibitor, to dissect the necessity of AURKA activity and the reversibility of its effects.
  • Competitive Co-culture: GFP-AURKA cells were seeded at a 1:10 ratio with parental cells to determine the propensity of AURKA-overexpressing cells to become leader cells.

• Molecular & Cytoskeletal Analysis:

  • Immunofluorescence (IF): Visualized centrosome polarization (RFP-TUBA1B), E-cadherin junctions, and actin dynamics (SPY650-FastAct).
  • Co-Immunoprecipitation (Co-IP): Validated physical interactions between AURKA and EPLIN (Epithelial Protein Lost In Neoplasia).
  • Live Imaging: Tracked microtubule and actin dynamics in real-time during migration.

3. Key Contributions

• AURKA as a Metastatic Driver: Demonstrated that AURKA expression is not merely a marker of proliferation but is sufficient to endow non-malignant breast epithelial cells with metastatic capabilities (engraftment and outgrowth) in a living organism.
• Leader Cell Specification: Identified AURKA as a critical determinant of the leader cell phenotype. AURKA expression drives centrosome polarization to the leading edge, a defining feature of leader cells.
• Mechanism of Cohesion: Uncovered a novel non-mitotic role for AURKA in maintaining cell-cell adhesion. It prevents the scattering of follower cells by stabilizing E-cadherin contacts.
• AURKA-EPLIN Axis: Discovered a direct physical and functional interaction between AURKA and the actin regulator EPLIN. AURKA activity is required to localize EPLIN to cell-cell junctions; without it, EPLIN mislocalizes to lamellipodia, causing junctional dissolution.

4. Key Results

• Clinical Correlation:

  • Metastatic sites (axilla, liver) showed significant enrichment of "G2/M checkpoint" and "mitotic spindle" pathways, which strongly correlated with AURKA expression.
  • High AURKA expression was significantly associated with poor overall survival (OS) and progression-free interval (PFI) across multiple cancer types, including breast cancer (HR=1.17).

• In Vivo Metastasis:

  • MCF10A cells overexpressing GFP-AURKA formed metastatic outgrowths in chicken embryos (detected in 24% of injected embryos), whereas control cells did not.
  • GFP-AURKA onplants showed denser cores and invasive cellular strands expressing heterogeneous markers (E-cadherin, K14, Vimentin), indicating a hybrid E/M state conducive to invasion.

• Leader Cell Dynamics:

  • In scratch assays, endogenous leader cells upregulated AURKA and K14 expression and polarized their centrosomes to the front within 1–3 hours of wounding.
  • Overexpression of GFP-AURKA increased the number of leader cells and accelerated wound closure.
  • In competitive assays, GFP-AURKA cells were significantly enriched as leader cells compared to controls.

• Inhibition Effects (MLN8237):

  • Inhibiting AURKA activity caused immediate cell scattering (loss of collective migration) and loss of directionality in leader cells.
  • E-cadherin intensity at leader-follower junctions decreased significantly.
  • Rescue Experiment: Co-treatment with the proteasome inhibitor MG132 reversed the scattering and restored E-cadherin levels, suggesting AURKA inhibition leads to proteasomal degradation of adhesion complexes.

• Molecular Mechanism (EPLIN):

  • AURKA physically interacts with EPLIN.
  • In control cells, EPLIN co-localizes with E-cadherin at cell-cell contacts.
  • Upon AURKA inhibition, EPLIN is relocalized to the lamellipodia (leading edge), coinciding with the disassembly of adherens junctions and the scattering of follower cells.

5. Significance

• Therapeutic Potential: The study identifies AURKA as a critical vulnerability in the metastatic process. Inhibiting AURKA disrupts the "leader-follower" architecture required for collective invasion, potentially halting metastasis before it establishes distant colonies.
• Novel Mechanism: It establishes a direct link between a mitotic kinase (AURKA) and the regulation of cell-cell adhesion via the actin-binding protein EPLIN in non-dividing, migrating cells.
• Clinical Relevance: Given that AURKA amplification is common in aggressive breast cancers and that AURKA inhibitors (like Alisertib) are already in clinical trials, these findings support the repurposing of AURKA inhibitors specifically to target the metastatic spread of breast carcinoma, potentially in combination with other therapies (e.g., endocrine therapy).
• Paradigm Shift: Challenges the view that AURKA's role is limited to mitosis, highlighting its essential function in cytoskeletal dynamics and tissue architecture during invasion.

In conclusion, the paper demonstrates that AURKA expression is sufficient to drive metastasis by creating leader cells and maintaining the structural integrity of migrating cell clusters through the AURKA-EPLIN-E-cadherin axis.